Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2023 Financial Results and Business Highlights - Seite 2

2022

Favorable /
(Unfavorable)

 

2023

2022

Favorable /
(Unfavorable)

$

%

$

%

Total revenues

1,597

 

1,570

 

27

2

%

4,160

 

6,674

 

(2,514

)

(38

%)

Total operating expenses

4,839

 

5,561

 

722

13

%

14,734

 

16,023

 

1,289

 

8

%

Loss from continuing
operations

(3,242

)

(3,991

)

749

19

%

(10,574

)

(9,349

)

(1,225

)

(13

%)

Net loss attributable to
common stockholders

(2,567

)

(2,867